Shigella, WRSs2 vaccine, efficacy, controlled human infection model, randomized controlled trial
Pneumococcal conjugate vaccine, reduced-dose schedule, non-inferiority, long-term immunogenicity, South Africa, HIV-unexposed, PCV13, PCV10